Studies evaluating TAS-102 and ctDNA are highlighted in ASCO GI 2021 - Onco Americas
Mode of action of TAS-102. α,α,α-Trifluorothymidine (FTD) is converted... | Download Scientific Diagram
TAS-102 (Trifluridine-tipiracil hydrochloride mixture) | Nucleoside Antimetabolite/Analog Inhibitor | Cas# 733030-01-8 - GlpBio
File:TAS-102 - Fluridine and Tipiracil Mechanism of Action.png - Wikipedia
TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies - ScienceDirect
Comparison of the mechanisms of action of TAS-102 and 5-FU. 5-FU... | Download Scientific Diagram
Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO. - ppt download
TAS-102 | ≥99%(HPLC) | Trifluridine-tipiracil hydrochloride mixture | AdooQ®
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer | Anticancer Research
File:TAS-102 - Fluridine and Tipiracil Mechanism of Action (2).svg - Wikimedia Commons
Department of Clinical Oncology
TAS-102 (trifluridine/tipiracil)…ยาสูตรผสมสำหรับรักษาโรคมะเร็งลำไส้ใหญ่และไส้ตรง
TAS-102 | Trifluridine | Tipiracil | CAS#733030-01-8 | CAS#183204-74-2 | CAS#70-00-8 | Thymidine Phhosphorylase Inhibitor | Cytotoxic Pyrimidine Analog | MedKoo
TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer? - The Lancet Oncology
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer - ScienceDirect
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial - The Lancet Oncology
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination - ScienceDirect
Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer | Anticancer Research
Regorafenib TAS-102 or TAS-102 Regorafenib - ppt download
SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer | CCO
File:TAS-102 - Fluridine and Tipiracil Mechanism of Action (2).svg - Wikimedia Commons
Full article: TAS-102 for the treatment of metastatic colorectal cancer
